FENC FENNEC PHARMACEUTICALS INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1211583 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY71.1%
TTM net income YoY129.2%
TTM EPS YoY111.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin5.6%
Net margin3.1%
FCF margin—
EBITDA margin—
Returns
ROE9.1%
ROA3.1%
ROIC (approx.)—
Asset turnover1.00x
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.00x
Current ratio6.11x
Interest coverage11.66x
Cash quality & payout
Operating cash flow / net income1.55x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $44.64M | $47.54M | $21.25M | $1.53M | — |
| Cost of revenue | — | — | $1.26M | $86,000 | — |
| Gross profit | — | — | $19.99M | $1.45M | — |
| R&D expense | $250,000 | $307,000 | $56,000 | $3.53M | $4.98M |
| SG&A expense | $28.29M | $23.05M | $20.59M | $17.72M | $12.24M |
| Operating income | -$6.28M | $2.57M | -$12.77M | -$22.59M | -$17.22M |
| Interest expense | $2.08M | $4.07M | $3.39M | — | — |
| Pretax income | -$9.63M | -$71,000 | -$16.05M | -$10.55M | -$9.12M |
| Income tax | $106,000 | $365,000 | — | $0 | $0 |
| Net income | -$9.74M | -$436,000 | -$16.05M | -$23.71M | -$17.35M |
| EPS (basic) | -0.34 | -0.02 | -0.60 | -0.90 | -0.67 |
| EPS (diluted) | -0.34 | -0.02 | -0.60 | -0.90 | -0.67 |
| Weighted avg. shares (diluted) | 28.58M | 27.29M | 26.57M | 26.27M | 26.01M |
| Banking | |||||
| Net interest income | — | — | $441,000 | $195,000 | — |
| Balance sheet | |||||
| Cash & equivalents | $36.79M | $26.63M | $13.27M | $23.77M | $21.10M |
| Current assets | $67.04M | $44.12M | $26.86M | $26.73M | $22.39M |
| Total assets | $70.55M | $44.95M | $26.86M | $26.94M | $22.41M |
| Current liabilities | $10.52M | $6.92M | $7.55M | $4.61M | $1.65M |
| Long-term debt | — | $19.34M | $30.93M | $24.90M | $5.00M |
| Total debt | — | $19.34M | $30.93M | $24.90M | $5.00M |
| Total liabilities | $35.08M | $50.82M | $38.49M | $29.51M | $6.64M |
| Shareholders' equity | $35.47M | -$5.87M | -$11.62M | -$2.57M | $15.77M |
| Net debt | — | -$7.30M | $17.66M | $1.12M | -$16.10M |
| Shares outstanding | 34.16M | 27.53M | 27.03M | 26.36M | 26.01M |
| Cash flow statement | |||||
| Operating cash flow | -$12.47M | $26.98M | -$17.14M | -$18.06M | -$14.22M |
| Financing cash flow | $22.63M | -$13.62M | $6.64M | $20.73M | $4.98M |
| Stock-based compensation | $7.03M | $5.06M | $5.35M | $4.09M | $3.75M |
Free plan shows the latest 5 periods; Pro shows all 28 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.